Filing identity and reporting period
Important discrepancy: The supplied filing is for Trail One, Inc., not Citius Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended June 30, 2014, covering the three- and nine-month periods ended that date. The summary below reflects Trail One’s filing and should not be attributed to Citius Pharmaceuticals.
Business context and financial results
Trail One planned to develop and sell customized automobile license-plate tags. It reported no sales revenue to date and described its operations as requiring additional financing.
| Metric | Three months ended June 30, 2014 | Nine months ended June 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $5,975 | $16,004 | $3,436 / $13,408 |
| Interest expense | $322 | $663 | $996 / $2,673 |
| Net loss | $6,297 | $16,667 | $4,432 / $16,081 |
No meaningful revenue-based margin was reported. Basic and diluted loss per share was shown as $(0.00) for each period; weighted-average shares were 18 million.
Financial position, cash flow, and changes
- At June 30, 2014, cash and total assets were $0. Current liabilities were $31,351, comprising $1,481 accounts payable, $29,196 notes payable, and $674 accrued interest. Working capital and stockholders’ equity were both negative $31,351.
- Accumulated deficit increased to $111,883 from $95,216 at September 30, 2013. Common shares outstanding remained 18 million.
- For the nine months, operating cash use was $25,997 and financing cash provided was $25,997, leaving ending cash at $0. Financing included $25,996 of Highline Research Advisors loans, unsecured, bearing 5% interest and due on demand.
- Compared with 2013, nine-month operating expenses rose $2,596, while interest expense declined $2,010; net loss increased $586, or about 4%. Quarterly operating expenses increased $2,539 and net loss rose $1,865, or about 42%.
Outlook, risks, and unusual items
- Management said existing liquidity was insufficient for at least the next 12 months, and expected revenue would not cover expenses. It cited a monthly burn rate of approximately $2,099 and said further equity or debt financing was needed; availability and terms were uncertain.
- The filing states that recurring losses, no revenue, zero cash, and a working-capital deficit raise substantial doubt about the company’s ability to continue as a going concern. Failure to obtain financing could force substantial cost reductions or cessation of operations.
- Management was negotiating on a non-binding basis a possible reverse merger with another business. A transaction could involve issuing shares, changing control, and assuming the acquired business’s liabilities; there was no assurance it would be completed.
- Subsequent event: on July 23, 2014, Highline provided a $1,481 unsecured loan, due on demand and bearing 5% interest.
- Disclosure controls were deemed ineffective. The filing cited no independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for financial reporting.
- The filing reported no material pending legal proceedings and no material off-balance-sheet arrangements. No conventional revenue or earnings guidance was provided.
Important facts for investors to verify
- Confirm the issuer: the submitted 10-Q identifies Trail One, Inc., not Citius Pharmaceuticals, Inc.
- Verify the status and terms of the proposed reverse merger and whether it was completed.
- Review subsequent financing, repayment terms, and the company’s ability to meet demand debt and other obligations.
- Assess the going-concern disclosure, zero-cash position, and plans to obtain capital.
- Check whether the disclosed control weaknesses were remediated and confirm current share count and ownership.